GT Biopharma, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the nine months ended September 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended)adopted, amended, orterminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.
Equity Awards
On August 19, 2025, the Compensation Committee of the Board and the Board approved new stock option awards pursuant to the Plan for management and non-employee members of the Board. Michael Breen, the Company’s Executive Chairman and Chief Executive Officer, was awarded (i) 100,000 stock options for 2024, fully vested upon issuance, (ii) 100,000 stock options for 2025, vesting quarterly through 2025, and (iii) 100,000 stock options for 2026, vesting quarterly through 2026. Alan Urban, the Company’s Chief Financial Officer, was awarded (i) 50,000 stock options for 2025, vesting quarterly through 2025, and (ii) 50,000 stock options for 2026, vesting quarterly through 2026.
Charles J. Casamento, a non-employee member of our Board, was awarded 31,250 stock options for the 2024-2025 period, fully vested upon issuance. Each non-employee member of our Board was awarded 31,250 stock options for the 2025-2026 period, fully vested upon issuance.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.